Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 38.7x - 42.8x | 40.7x |
| Selected Fwd Revenue Multiple | 11.5x - 12.7x | 12.1x |
| Fair Value | kr6.35 - kr6.94 | kr6.64 |
| Upside | -29.0% - -22.4% | -25.7% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| ALK-Abelló A/S | ALK B | CPSE:ALKB |
| DanCann Pharma A/S | DANCAN | NGM:DANCAN |
| Stenocare A/S | STENO | CPSE:STENO |
| Pharma Equity Group A/S | PEG | CPSE:PEG |
| H. Lundbeck A/S | HLUN A | CPSE:HLUNA |
| Cessatech A/S | CESSA | NGM:CESSA |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| ALK B | DANCAN | STENO | PEG | HLUN A | CESSA | |||
| CPSE:ALKB | NGM:DANCAN | CPSE:STENO | CPSE:PEG | CPSE:HLUNA | NGM:CESSA | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 11.1% | NM- | -14.7% | NM- | 5.3% | NM- | ||
| 3Y CAGR | 12.2% | 49.9% | 5.7% | NM- | 10.5% | NM- | ||
| Latest Twelve Months | 14.8% | 8.5% | -44.1% | NM | 10.5% | NM | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | 10.0% | -573.4% | -2207.9% | NA | 16.3% | -610.2% | ||
| Prior Fiscal Year | 13.8% | -840.4% | -399.4% | NA | 18.0% | NA | ||
| Latest Fiscal Year | 19.8% | -86.1% | -897.9% | NA | 19.9% | -766.4% | ||
| Latest Twelve Months | 19.8% | -86.1% | -897.9% | NA | 19.9% | -766.4% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 5.70x | 0.58x | 4.81x | NA | 2.28x | 58.81x | ||
| EV / LTM EBIT | 28.8x | -0.7x | -0.5x | -8.6x | 11.5x | -7.7x | ||
| Price / LTM Sales | 5.59x | 0.89x | 3.76x | NA | 1.74x | 63.78x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 0.58x | 3.55x | 5.70x | |||||
| Historical EV / LTM Revenue | 58.81x | 58.81x | 58.81x | |||||
| Selected EV / LTM Revenue | 38.70x | 40.73x | 42.77x | |||||
| (x) LTM Revenue | 2 | 2 | 2 | |||||
| (=) Implied Enterprise Value | 96 | 101 | 106 | |||||
| (-) Non-shareholder Claims * | 12 | 12 | 12 | |||||
| (=) Equity Value | 109 | 114 | 119 | |||||
| (/) Shares Outstanding | 17.4 | 17.4 | 17.4 | |||||
| Implied Value Range | 6.23 | 6.52 | 6.81 | |||||
| FX Rate: DKK/DKK | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 6.23 | 6.52 | 6.81 | 8.94 | ||||
| Upside / (Downside) | -30.3% | -27.1% | -23.8% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | ALK B | DANCAN | STENO | PEG | HLUN A | CESSA | |
| Enterprise Value | 31,144 | 4 | 10 | 179 | 47,005 | 143 | |
| (+) Cash & Short Term Investments | 589 | 3 | 1 | 4 | 4,664 | 12 | |
| (+) Investments & Other | 0 | 0 | 0 | 0 | 67 | 0 | |
| (-) Debt | (1,187) | (1) | (4) | (11) | (16,693) | 0 | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 30,546 | 7 | 7 | 172 | 35,043 | 156 | |
| (/) Shares Outstanding | 221.2 | 4.0 | 20.0 | 1,227.5 | 1,128.7 | 17.4 | |
| Implied Stock Price | 138.10 | 1.70 | 0.37 | 0.14 | 31.05 | 8.94 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 138.10 | 1.70 | 0.37 | 0.14 | 31.05 | 8.94 | |
| Trading Currency | DKK | DKK | DKK | DKK | DKK | DKK | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |